Origen Therapeutics
Burlingame
About Origen Therapeutics
Origen Therapeutics, Inc., a biotechnology company, develops products from avian transgenic animal technology. It provides human sequence polyclonal antibodies. The company also develops a technology platform based on the genetic engineering of chicken embryonic cells, which can be genetically modified in such a way that the introduced genes are stably expressed in adult birds. Origen Therapeutics, Inc. was incorporated in 1997 and is based in Burlingame, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $5.7M
- Last round: Series Unknown (Aug 2010)
- Website: origentherapeutics.com
- Phone: +1 650-558-6700
Industries & Categories
Biotechnology, Genetics
Canonical: https://fsome.com/organization/origen-therapeutics-2904096 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.